Back

This discussion focuses on the evolving role of first line maintenance therapy in extensive stage small cell lung cancer, with focused discussion of the phase 3 IMforte trial evaluating atezolizumab plus lurbinectedin. Faculty review efficacy data, safety considerations, patient selection, management of brain metastases, and case based decision making to contextualize how maintenance strategies are being integrated into contemporary practice.

First-Line Maintenance Strategies in Extensive-Stage Small Cell Lung Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: First Line Maintenance in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 6th 2026

Experts unpack IMfortis data on intensifying atezolizumab maintenance after induction chemoimmunotherapy in extensive-stage small cell lung cancer.

EP. 2: Reviewing the IMforte Phase 3 Data in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 6th 2026

IMforté data show larotrectinib plus atezolizumab maintenance extends PFS and OS in extensive-stage small cell lung cancer—real-world considerations.

EP. 3: Safety Profile of Lurbinectedin and Patient Selection for Maintenance Therapy

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 13th 2026

Experts weigh IMfortis data, side effects, and patient selection as lurbinectedin-atezolizumab maintenance reshapes extensive-stage SCLC care.

EP. 4: Management of Brain Metastases in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 13th 2026

Experts weigh brain metastases limits in IMFORTA and share real-world tips for maintenance lurbinectedin plus atezolizumab.

EP. 5: Applying IMforte Data to a Clinical Scenario

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 20th 2026

Experts weigh maintenance options after chemo-immunotherapy in extensive-stage SCLC, navigating brain mets, cytopenias, and real-world care barriers.

EP. 6: Dosing Strategies and Real World Implementation of Maintenance Therapy

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 20th 2026

Relapsed small cell lung cancer care evolves as tarlatamab boosts survival but needs CRS/ICANS monitoring, while lurbinectedin offers simpler dosing.

EP. 7: Future of Optimal Maintenance Therapy in ES-SCLC

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 27th 2026

Experts explore biomarkers, sequencing, and access strategies for extensive-stage small cell lung cancer maintenance, spotlighting tarlatamab, ADC combos, and clinical trials.

First-Line Maintenance Strategies in Extensive-Stage Small Cell Lung Cancer

Episodes

EP. 1: First Line Maintenance in Extensive Stage Small Cell Lung Cancer

EP. 2: Reviewing the IMforte Phase 3 Data in Extensive Stage Small Cell Lung Cancer

EP. 3: Safety Profile of Lurbinectedin and Patient Selection for Maintenance Therapy

EP. 4: Management of Brain Metastases in Extensive Stage Small Cell Lung Cancer

EP. 5: Applying IMforte Data to a Clinical Scenario

EP. 6: Dosing Strategies and Real World Implementation of Maintenance Therapy

EP. 7: Future of Optimal Maintenance Therapy in ES-SCLC

Trending on OncLive

Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma

FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma

Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma

Trastuzumab Rezetecan Elicits High ORR in HER2-High and HER2-Low Salivary Gland Carcinoma

OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?